Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Immunoglobulin for Severe COVID-19 Pneumonia
NCT04264858Unknown
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label trial of convalescent immunoglobulin in COVID-19 pneumonia (2 arms). Primary endpoint: Time to Clinical Improvement at 28 days. Status: unknown.
02
Drugs
convalescent immunoglobulin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04264858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264858.